TSN 222
Alternative Names: TSN-222Latest Information Update: 06 Apr 2026
At a glance
- Originator Tyligand Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Malignant melanoma; Solid tumours
Most Recent Events
- 17 Oct 2025 Adverse event and efficacy data from phase I/II trial in Solid tumors presented at 50th European Society for Medical Oncology Congress (ESMO-2025)
- 28 Aug 2025 Efficacy, pharmacokinetic, pharmacodynamic and adverse event data from phase I/II in Solid tumors presented at the 116th Annual Meeting of the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 25 Apr 2025 Efficacy and adverse event data from phase I/II in Solid tumors and Lymphoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)